Dr. Kanhaiya Singh received his doctoral degree in Biotechnology from Banaras Hindu University, India. Prior to joining the McGowan Institute and the University of Pittsburgh, Dr. Singh served as Assistant Professor of Surgery, Division of Plastic Surgery, Department of Surgery at Indiana University. He completed his post-doctoral research at The Ohio State University.

Dr. Singh’s laboratory focuses on epigenetics of diabetic vasculopathy and wound healing.

His laboratory is investigating epigenetic mechanisms such as DNA methylation as a proxy for abnormal gene–environmental interactions in diabetic ischemic wounds. The lab’s current line of study aims to develop a simple and point-of-care approach to achieve targeted epigenetic editing of adult diabetic ischemic tissue in vivo. The research is funded through a grant from the U.S. Department of Defense (DoD).

His laboratory is also investigating the molecular mechanism in diabetic vasculopathy and limb ischemia. Researchers are applying single-cell RNA sequencing technology to study the endothelial cells of the human diabetic skin in order to identify novel ligands and receptors that can improve outcomes of the vascular endothelial growth factor (VEGF) therapy. To that end, his team is employing tissue nanotransfection technology as a delivery platform to administer combination gene therapy for diabetic ischemic limb rescue.

Dr. Singh serves as an editorial board member for Nature’s Scientific Reports, an academic editor for PLOS ONE, editor for Genetics Research, guest editor for Oxidative Medicine and Cellular Longevity and Frontiers in Endocrinology, and an editorial board member for NewBioWorld.

View a list of Dr. Singh’s publications here.